Government-Owned Inventions; Availability for Licensing, 74546-74549 [E6-21028]
Download as PDF
74546
Federal Register / Vol. 71, No. 238 / Tuesday, December 12, 2006 / Notices
active duty service obligation prescribed
under section 338A of the Public Health
Service Act (42 U.S.C. 254l) by a
program specified in options (1)–(4)
above that:
(i) Is located on the reservation of the
Tribe in which the recipient is enrolled;
or
(ii) Serves the Tribe in which the
recipient is enrolled.
In summary, all recipients of the
Indian Health Scholarship (Health
Professions) are reminded that
recipients of this scholarship incur a
service obligation. Moreover, this
obligation shall be served at a facility
determined by the Director, IHS,
consistent with IHCIA, Pub. L. 94–437,
as amended by Public Law 100–713,
and Public Law 102–573.
3. Reporting
jlentini on PROD1PC65 with NOTICES
Scholarship Program Minimum
Academic Requirements
It is the policy of the IHS that a
scholarship recipient awarded under the
Health Professions Scholarship Program
of the Indian Health Care Improvement
Act maintain a 2.0 cumulative grade
point average (GPA) each semester/
quarter and be a full-time student
(minimum of 12 credit hours considered
by your school as full-time). A recipient
of a scholarship under the Health
Professions Pre-Graduate and Health
Professions Preparatory Scholarship
authority must maintain a good
academic standing each semester/
quarter and be a full time student
(minimum of 12 credit hours or the
number of credit hours considered by
your school as full-time). In addition to
the two requirements stated above, a
Health Professions Scholarship program
grantee must be enrolled in an
approved/accredited school for a health
professions degree. Part-time students
for the three scholarship programs must
also maintain a 2.0 cumulative GPA and
must take at least 6 credit hours each
semester/quarter but less than the
number of hours considered full-time by
your school. Scholarship grantees must
be approved for part-time status at the
time of scholarship award. Scholarship
grantees may not change from part-time
status to full-time status or vice versa in
the same academic year.
The following reports must be sent to
the IHS Scholarship Program at the
identified time frame. Each scholarship
grantee will be provided with an IHS
Scholarship Handbook where the below
needed reports are located. If a
scholarship grantee fails to submit these
reports as required, they will be
ineligible for continuation of
VerDate Aug<31>2005
18:00 Dec 11, 2006
Jkt 211001
scholarship support and scholarship
award payments will be discontinued.
A. Recipient’s Enrollment and Initial
Progress Report
Within thirty (30) days from the
beginning of each semester or quarter,
scholarship grantees must submit a
Recipient’s Enrollment and Initial
Progress Report (Form F–02 of the
student handbook).
B. Transcripts
Within thirty (30) days from the end
of each academic period, i.e., semester,
quarter, or summer session, scholarship
grantees must submit an Official
Transcript showing the results of the
classes taken during that period.
C. Notification of Academic Problem/
Change
If at any time during the semester/
quarter, scholarship grantees are
advised to reduce the number of credit
hours for which they are enrolled below
the minimum of 12 (or the number of
hours considered by their school as full
time) for a full-time student or at least
6 hours for part-time students; or if they
experience academic problems, they
must submit this report (page F–04 of
student handbook).
D. Change of Status
• Change of Academic Status.
Scholarship Grantees must
immediately notify the IHS Area
Coordinator if they are placed on
academic probation, dismissed from
school, or voluntarily withdraw for any
reason (personal or medical).
• Change of Health Discipline.
Scholarship Grantees may not change
from the approved IHS Scholarship
Program health discipline during the
school year. If an unapproved change is
made, scholarship payments will be
discontinued.
• Change in Graduation Date.
Any time that a change occurs in a
scholarship grantee’s expected
graduation date, they must notify their
IHS Area Coordinator immediately in
writing. Justification must be attached
from the school advisor.
VII. Agency Contacts
Please address application inquiries
to the appropriate IHS Area
Coordinator. Other programmatic
inquiries may be addressed to Ms.
Patricia Lee McCoy, Director, Division
of Health Professions Support, Indian
Health Service, 801 Thompson Avenue,
Suite 120, Rockville, Maryland 20852;
Telephone (301) 443–6197. (This is not
a toll free number.) For grants
information, contact the Grants
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
Scholarship Coordinator, Division of
Grants Operations, Indian Health
Service, 801 Thompson Avenue, Suite
120, Rockville, Maryland 20852;
Telephone (301) 443–0243. (This is not
a toll-free number).
VIII. Other Information
The Public Health Service (PHS) is
committed to achieving the health
promotion and disease prevention
objectives of Healthy People 2010, a
PHS-led activity for setting priority
areas. This program announcement is
related to the priority area of Education
and Community-Based Programs.
Potential applicants may obtain a copy
of Healthy People 2010, (Full Report;
Stock No. 017–001–00474–0) or Healthy
People 2010 (Summary Report; Stock
No. 017–001–00473–1) through the
Superintendent of Documents,
Government Printing Office,
Washington, DC 20402–9325
[Telephone (202) 783–3238].
Interested individuals are reminded
that the list of eligible health and allied
health professions is effective for
applicants for the 2007–2008 academic
year. These priorities will remain in
effect until superseded. Applicants for
health and allied health professions not
on the above priority list will be
considered pending the availability of
funds and dependent upon the
availability of qualified applicants in
the priority areas.
Dated: December 4, 2006.
Robert G. McSwain,
Deputy Director, Indian Health Service.
[FR Doc. E6–21026 Filed 12–11–06; 8:45 am]
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
E:\FR\FM\12DEN1.SGM
12DEN1
Federal Register / Vol. 71, No. 238 / Tuesday, December 12, 2006 / Notices
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
jlentini on PROD1PC65 with NOTICES
Erythroid Progenitor Cells and Methods
for Producing Parvovirus B19 Therein
Description of Technology: The
present technology offers novel methods
of cell culture for production of human
parvovirus B19 (B19). B19, a common
infection of children adults, is the cause
of fifth disease. Symptoms of B19
infection are usually mild in otherwise
healthy individuals, but some adults
can suffer chronic arthopathy. Severe
health conditions and mortality may
result from B19 infection of
immunocompromised individuals and
patients with chronic hemolytic anemia
such as sickle cell disease. In addition,
B19 infection during pregnancy may
cause hydrops fetalis and fetal death.
There is no specific antiviral drug for
B19, and some forms of chronic
infection are difficult to diagnose.
Vaccination is an effective strategy for
other animal parvoviruses and is
feasible for B19 in humans.
B19 selectively infects erythroid
progenitor cells of bone marrow, fetal
liver and a small number of specialized
cell lines. These specific cell lines
demonstrate limited infectability and
commonly produce little or no virus
following initial inoculation with B19.
Current methods for producing
infectious B19 require phlebotomy of
infrequently available infected donors.
The available technology describes a
method of producing pure populations
of human erythroid progenitor cells that
are fully permissive to B19 infection.
This discovery uses CD34+
hematopoietic stem cells present in
peripheral blood to supply erythroid
progenitor cells, which demonstrate a
significant increase in viral production
after initial inoculation. The ability to
efficiently generate significant amounts
of infectious B19V in cells is useful for
the development of killed or attenuated
vaccines, therapeutics and efficient
diagnostic tools for prevention and
treatment of B19V. Furthermore, this
technology would allow development of
new diagnostic assays, which use the
entire virus as the antigenic target, thus
providing more sensitive and accurate
results than current diagnostic tools,
VerDate Aug<31>2005
18:00 Dec 11, 2006
Jkt 211001
which rely on antibodies against a
single viral protein.
Applications: (1) Diagnosis of human
parvovirus B19; (2) Vaccination of
individuals at risk for severe effects of
parvovirus infection; (3) Research and
development of anti-parvovirus agents.
Development Status: Preclinical data
is available at this time.
Inventors: Susan Wong and Neal
Young (NHLBI).
Related Publications: 1. MC
Giarratana, L Kobari, H Lapillonne, D
Chalmers, L Kiger, T Cynober, MC
Marden, H Wajcman, L Douay. Ex vivo
generation of fully mature human red
blood cells from hematopoietic stem
cells. Nat Biotechnol. 2005 Jan;
23(1):69–74.
2. JM Freyssinier, C Lecoq-Lafon, S
Amsellem, F Picard, R Ducrocq, P
Mayeux, C Lacombe, S Fichelson.
Purification, amplification and
characterization of a population of
human erythroid progenitors. Br J
Haematol. 1999 Sep; 106(4):912–922.
Patent Status: U.S. Provisional
Application No. 60/808,904 filed 26
May 2006 (HHS Reference No. E–188–
2006/0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing and
commercial development.
Licensing Contact: Chekesha S.
Clingman, Ph.D.; 301/435–5018;
clingmac@mail.nih.gov.
Collaborative Research Opportunity:
The NHLBI Hematology Branch is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
novel methods to produce parvovirus
B19 and use as diagnostic or vaccine.
Please contact Dr. Neal Young at 301–
496–5093, YoungNS@mail.nih.gov for
more information.
Small Molecules for Imaging ProteinProtein Interactions
Description of Technology: Imaging
techniques like positron emission
tomography and photon emission
computerized tomography are often
used with imaging agents to detect the
presence and accumulation of amyloid
plaques within the human brain. These
imaging agents have high specificity for
beta amyloid peptides, and
administration of such agents aids in the
early detection of amyloid plaques in
brains of Alzheimer’s victims. However,
currently available imaging agents have
limited success for detecting pre-plaque
beta amyloid proteins because they are
small and reside within the tissue for a
short period of time. Therefore, new
imaging agents are needed for enhanced
identification of amyloid deposits.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
74547
Available for licensing and
commercial development are small
molecules for imaging protein-protein
interactions in Alzheimer’s disease.
This technology describes a bifunctional
molecule with high specificity for beta
amyloid proteins that is applicable for
in vivo imaging. The molecule contains
two moieties with different binding
affinities, one moiety has an affinity for
amyloid beta proteins, and the other
moiety has an affinity for a tissuespecific chaperone. The different
moieties of the subject invention are
conjoined by an inert linkage group,
typically comprised of a hydrocarbon
chain, peptide, or carbohydrate. The
subject invention is affixed with a label,
such as a fluorophore or radioisotope,
which adheres to the binding site of the
beta amyloid protein, the chaperone, or
the linkage group. The choice of label
makes the subject invention versatile
and employable in several types of
imaging modalities such as single
photon emission computed tomography
(SPECT), positron emission tomography
(PET), magnetic resonance imaging
(MRI), and computerized tomography
(CT) scans.
Applications: (1) Applicable for
identification of beta amyloid plaques in
patients with or at risk for Alzheimer’s
disease and pre-plaque amyloid beta
proteins; (2) Applicable for in vivo
imaging protein-protein interactions
using small molecules; (3) Applicable
for image guided therapy of Alzheimer’s
disease.
Market: (1) Alzheimer’s disease affects
approximately 4.5 million people
within the United States; (2) The direct
and indirect annual costs associated
with Alzheimer’s disease are at least
$100 billion.
Development Status: Pre-clinical data
is available.
Inventors: King C. Li and S.
Narasimhan Danthi (CC).
Patent Status: U.S. Provisional
Application No. 60/815,740 filed 21 Jun
2006 (HHS Reference No. E–046–2006/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Chekesha S.
Clingman , Ph.D.; 301–435–5018;
clingmac@mail.nih.gov.
Collaborative Research Opportunity:
The National Institutes of Health
Clinical Center, Laboratory of Diagnostic
Radiology Research, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize Small Molecules for
Imaging Protein-Protein Interactions.
Please contact Betty Tong, Ph.D. at 301–
594–4263 for more information.
E:\FR\FM\12DEN1.SGM
12DEN1
74548
Federal Register / Vol. 71, No. 238 / Tuesday, December 12, 2006 / Notices
Systems and Methods for Intelligent
Quality Control of Instruments and
Processes
includes the capacity to identify
imprecision in a variety of data analysis
tools, which may be susceptible to
malfunction. Such processes include
instrumental analysis of patient
specimens, assembly line manufacturing
and general plant or factory operation.
This system provides an automated
platform for the dual purpose of (1)
monitoring data to detect unusual
events in real time and (2) enhancement
of human and machine recognition and
analysis of improper occurrences based
on time-varying patterns of measured
values.
The scheme of the current system is
straightforward and in general the
method involves the following steps: (1)
Collection of data elements from an
instrument or process (2) counting data
elements having values within
predetermined intervals of the data
range (3) applying counts of data to a
neural network that monitors data
trends and (4) production of an output
based on the neural network, which
demonstrates whether the instrument or
process is generating results within an
appropriate range. This system is
advantageous because output is
generated in real time and thus available
without delay for immediate correction
of malfunctions.
Applications: (1) Quality control for
processes and instruments; (2)
Automated system for real time
notification of malfunctions in an
instrument or process for immediate
correction of the procedure.
Development Status: The technology
is fully developed.
Inventors: James M. Deleo (CIT) and
Alan T. Remaley (CC).
Patent Status: U.S. Patent No.
6,556,951 issued 29 Apr 2003 (HHS
Reference No. E–042–1997/0–US–03).
Licensing Status: Available for nonexclusive and exclusive licensing.
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301–435–4507; thalhamc@mail.nih.gov.
Collaborative Research Opportunity:
The National Institutes of Health
Clinical Center, Radiologic and Imaging
Sciences, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize Intelligent Quality
Control of Instruments. Please contact
Elaine Ayres at 301/594–3019 for more
information.
Description of Technology: Available
for licensing and commercial
development is a cost-effective system
and method for evaluation of
instruments and processes for real-time
detection of error. The subject invention
Sample Delivery System With Laminar
Mixing for Microvolume Biosensing
Description of Invention: The
invention is a sample delivery system
with at least two microchannels
connected to a sample chamber
Methods and Systems for Identifying
and Classifying Drug Targets
jlentini on PROD1PC65 with NOTICES
Description of Technology: Available
for licensing and commercial
development is a novel method for apriori evaluation of the therapeutic
relevance of gene products for various
diseases, in order to make drug
development more cost-efficient. In
addition, this technology may be used to
identify novel therapeutic uses for
known drugs. For example, the current
invention has the potential to uncover
the role of an established cancer drug
target, in an alternative disorder such as
Alzheimer’s disease, thus providing an
additional use for the available cancer
drug.
The multivariable model used by the
method, which is based on a training set
of targets that have already passed FDA
review, is capable of ranking drug
targets in terms of prospective clinical
success. This innovative approach
integrates multiple datasets that
describe each single gene product from
a broad range of analyses, such as
microarrays, x-ray crystallography, and
phylogenetics, to rapidly characterize a
proteins structure, function, and gene
regulation information. An algorithm
subsequently scores a protein’s potential
as a drug target for use in future drug
design studies. The resulting set of
targets is enriched 28-fold as compared
to randomly selected gene products.
Applications: (1) Early evaluation of a
candidate drug target’s potential to yield
a therapeutic effect, given the target’s
inhibitor is provided; (2) Efficient
discovery of novel drugs and drug
targets; (3) Classification of genes
according to their involvement in
specific diseases.
Development Status: The technology
is ready to be used in drug discovery
and development.
Inventors: Anatoly L. Mayburd (NCI),
James L. Mulshine (NCI), et al.
Patent Status: U.S. Provisional
Application No. 60/788,522 filed 31 Mar
2006 (HHS Reference No. E–268–2005/
0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301–435–4507; thalhamc@mail.nih.gov.
VerDate Aug<31>2005
18:00 Dec 11, 2006
Jkt 211001
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
containing a biosensor. Biosensing for
studying molecular recognition has
become an important biophysical tool
for biomedical research. The system
aspirates a small sample volume into
the microfluidic channels and applies a
periodic oscillatory flow pattern to the
sample. This prevents sample depletion
in the stagnant layer across the sensor
surface and results in efficient mixing of
the sample during the biosensor
measurement. Because the oscillatory
flow pattern does not produce a net
transport of the sample with time, there
is a very long incubation time of the
sensor surfaces with a very small
sample volume. The new sample
delivery system uses sample volumes of
only 3 to 8 microliters, compared to the
25 to 200 microliter volumes of
conventional systems, which use
cuvette principles or continuous flow
microfluidics. The present invention is
substantially better than existing
systems with respect to biosensor
contact time and required sample
volume.
Application: Sample delivery for
biosensing.
Development Status: A prototype of
the technology is currently being
implemented in inventor’s lab and
technology is ready for
commercialization.
Inventor: Peter Schuck (ORS).
Publication: M Abrantes, MT Magone,
LF Boyd, P Schuck. Adaptation of a
surface plasmon resonance biosensor
with microfluidics for use with small
sample volumes and long contact times.
Anal Chem. 2001 Jul 1;73(13):2828–
2835.
Patent Status: U.S. Patent Application
No. 10/415,909 filed 05 May 2003,
claiming priority to 06 Nov 2000 (HHS
Reference No. E–143–2000/0–US–03);
European Patent Application No.
01990651.0 filed 11 Jun 2001 (HHS
Reference No. E–143–2000/0–EP–04).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Michael A.
Shmilovich, Esq.; 301/435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The NIH Office of Research Services,
Division of Bioengineering and Physical
Science, Protein Biophysics Resource, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize this
Sample Delivery System technology.
Please contact Dr. Peter Schuck at 301–
435–1950 or pschuck@helix.nih.gov for
more information.
E:\FR\FM\12DEN1.SGM
12DEN1
Federal Register / Vol. 71, No. 238 / Tuesday, December 12, 2006 / Notices
Vaccine for Dengue Virus
Description of Technology: The
claimed invention relates to viable
chimeric dengue viruses or their derived
recombinant mutants for use as vaccines
against dengue and other flavivirus
diseases, including tick-borne
encephalitis and West Nile encephalitis.
Dengue is a mosquito-transmitted viral
disease which occurs in tropical and
subtropical regions throughout the
world. Inactivated whole dengue virus
vaccines have been shown to be
insufficiently immunogenic and live
dengue virus vaccines prepared by
serial passage in cell culture have not
been shown to be consistently
attenuated. A dengue vaccine is still not
available. The present invention
represents a technical breakthrough,
which provides new approaches to
dengue vaccines by construction of
chimeric dengue viruses of all four
serotypes and strategic modification to
produce attenuated virus strains.
Several fields of use remain available for
licensing.
Applications: Prevention of dengue
outbreaks, severe and fatal dengue
caused by dengue viruses, a major
public health problem in tropical and
subtropical regions.
Inventors: Ching-juh Lai, et al.
(NIAID).
Patent Status: U.S. Patent 6,184,024
issued 06 Feb 2001 (HHS Reference No.
E–171–1988/1–US–02); U.S. Patent
6,676,926 issued 13 Jan 2004 (HHS
Reference No. E–171–1988/1–US–03).
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301–435–4646;
soukasp@mail.nih.gov.
jlentini on PROD1PC65 with NOTICES
Murine Monoclonal Antibodies
Effective To Treat Respiratory
Syncytial Virus
Description of Technology: Available
for licensing through a Biological
Materials License Agreement are the
murine MAbs described in Beeler et al,
‘‘Neutralization epitopes of the F
glycoprotein of respiratory syncytial
virus: effect of mutation upon fusion
function,’’ J Virol. 1989 Jul;63(7):2941–
2950. The MAbs that are available for
licensing are the following: 1129, 1153,
1142, 1200, 1214, 1237, 1112, 1269, and
1243. One of these MAbs, 1129, is the
basis for a humanized murine MAb (see
U.S. Patent 5,824,307 to humanized
1129 owned by MedImmune, Inc.),
recently approved for marketing in the
United States. MAbs in the panel
reported by Beeler et al. have been
shown to be effective therapeutically
when administered into the lungs of
VerDate Aug<31>2005
18:00 Dec 11, 2006
Jkt 211001
cotton rats by small-particle aerosol.
Among these MAbs several exhibited a
high affinity (approximately 109M–1)
for the RSV F glycoprotein and are
directed at epitopes encompassing
amino acid 262, 272, 275, 276 or 389.
These epitopes are separate,
nonoverlapping and distinct from the
epitope recognized by the human Fab of
U.S. Patent 5,762,905 owned by The
Scripps Research Institute.
Applications: Research and drug
development for treatment of respiratory
syncytial virus.
Inventors: Robert M. Chanock, Brian
R. Murphy, Judith A. Beeler, and
Kathleen L. van Wyke Coelingh (NIAID).
Patent Status: HHS Reference No. B–
056–1994/1—Research Tool.
Licensing Status: Available for nonexclusive licensing under a Biological
Materials License Agreement.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov.
Dated: December 1, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–21028 Filed 12–11–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
74549
be required to receive copies of the
patent applications.
Noncovalent HIV Env-CD4 Complexes
as HIV Vaccines
Description of Technology: HIV
vaccine technology based on HIV
envelope protein (Env) have been less
successful than anticipated to date. One
possible reason for this is the potential
conformational masking of neutralizing
epitopes. The current technology
combines HIV Env and cell surface
polypeptides CD4 in non-covalent
complexes to expose epitopes not
present on the uncomplexed Env
molecules. These complexes can thus be
used to elicit neutralizing antibodies
when used as vaccines, immunogenic
compositions or immunotherapies. The
CD4 inducing epitopes found in regions
of the virus that are most conserved
across clades are unmasked and
immune sera generated with this
technology neutralized primary HIV–1
viruses from several clades.
Additionally, cell surface polypeptide
CD4 is in its native conformation and
masked by Env, therefore it is unlikely
to induce autoantibodies.
Applications and Advantages: (1) HIV
vaccine based on conformationally
masked epitopes; (2) Presents epitopes
to immune system that are the same or
similar as with actual HIV infection; (3)
Multiple copies of Env may enhance
immune response and limit dosage.
Inventors: Jinhai Wang and Michael
Norcross (CDER/FDA).
Patent Status: U.S. Provisional
Application No. 60/711,985 filed 25
Aug 2005 (HHS Reference No. E–173–
2005/0–US–01); PCT Application filed
25 Aug 2006 (HHS Reference No. E–
173–2005/1–PCT–01).
Licensing Contact: Susan Ano, PhD;
301–435–5515; anos@mail.nih.gov.
Collaborative Research Opportunity:
The FDA Center for Drug Evaluation
and Research is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this HIV Env-CD4
technology. Please contact Beatrice A.
Droke at 301/827–7008 or
bea.droke@fda.hhs.gov for more
information.
Modified Bacterial Strain for Otitis
Media Vaccine
Description of the Technology: This
invention relates to a strain of Moraxella
catarrhalis containing a gene mutation
that prevents endotoxic
lipooligosaccharide (LOS) synthesis and
potential use of the mutant for
developing novel vaccines against the
pathogen, for which there is currently
E:\FR\FM\12DEN1.SGM
12DEN1
Agencies
[Federal Register Volume 71, Number 238 (Tuesday, December 12, 2006)]
[Notices]
[Pages 74546-74549]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-21028]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
[[Page 74547]]
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Erythroid Progenitor Cells and Methods for Producing Parvovirus B19
Therein
Description of Technology: The present technology offers novel
methods of cell culture for production of human parvovirus B19 (B19).
B19, a common infection of children adults, is the cause of fifth
disease. Symptoms of B19 infection are usually mild in otherwise
healthy individuals, but some adults can suffer chronic arthopathy.
Severe health conditions and mortality may result from B19 infection of
immunocompromised individuals and patients with chronic hemolytic
anemia such as sickle cell disease. In addition, B19 infection during
pregnancy may cause hydrops fetalis and fetal death. There is no
specific antiviral drug for B19, and some forms of chronic infection
are difficult to diagnose. Vaccination is an effective strategy for
other animal parvoviruses and is feasible for B19 in humans.
B19 selectively infects erythroid progenitor cells of bone marrow,
fetal liver and a small number of specialized cell lines. These
specific cell lines demonstrate limited infectability and commonly
produce little or no virus following initial inoculation with B19.
Current methods for producing infectious B19 require phlebotomy of
infrequently available infected donors.
The available technology describes a method of producing pure
populations of human erythroid progenitor cells that are fully
permissive to B19 infection. This discovery uses CD34+ hematopoietic
stem cells present in peripheral blood to supply erythroid progenitor
cells, which demonstrate a significant increase in viral production
after initial inoculation. The ability to efficiently generate
significant amounts of infectious B19V in cells is useful for the
development of killed or attenuated vaccines, therapeutics and
efficient diagnostic tools for prevention and treatment of B19V.
Furthermore, this technology would allow development of new diagnostic
assays, which use the entire virus as the antigenic target, thus
providing more sensitive and accurate results than current diagnostic
tools, which rely on antibodies against a single viral protein.
Applications: (1) Diagnosis of human parvovirus B19; (2)
Vaccination of individuals at risk for severe effects of parvovirus
infection; (3) Research and development of anti-parvovirus agents.
Development Status: Preclinical data is available at this time.
Inventors: Susan Wong and Neal Young (NHLBI).
Related Publications: 1. MC Giarratana, L Kobari, H Lapillonne, D
Chalmers, L Kiger, T Cynober, MC Marden, H Wajcman, L Douay. Ex vivo
generation of fully mature human red blood cells from hematopoietic
stem cells. Nat Biotechnol. 2005 Jan; 23(1):69-74.
2. JM Freyssinier, C Lecoq-Lafon, S Amsellem, F Picard, R Ducrocq,
P Mayeux, C Lacombe, S Fichelson. Purification, amplification and
characterization of a population of human erythroid progenitors. Br J
Haematol. 1999 Sep; 106(4):912-922.
Patent Status: U.S. Provisional Application No. 60/808,904 filed 26
May 2006 (HHS Reference No. E-188-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing and commercial development.
Licensing Contact: Chekesha S. Clingman, Ph.D.; 301/435-5018;
clingmac@mail.nih.gov.
Collaborative Research Opportunity: The NHLBI Hematology Branch is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
novel methods to produce parvovirus B19 and use as diagnostic or
vaccine. Please contact Dr. Neal Young at 301-496-5093,
YoungNS@mail.nih.gov for more information.
Small Molecules for Imaging Protein-Protein Interactions
Description of Technology: Imaging techniques like positron
emission tomography and photon emission computerized tomography are
often used with imaging agents to detect the presence and accumulation
of amyloid plaques within the human brain. These imaging agents have
high specificity for beta amyloid peptides, and administration of such
agents aids in the early detection of amyloid plaques in brains of
Alzheimer's victims. However, currently available imaging agents have
limited success for detecting pre-plaque beta amyloid proteins because
they are small and reside within the tissue for a short period of time.
Therefore, new imaging agents are needed for enhanced identification of
amyloid deposits.
Available for licensing and commercial development are small
molecules for imaging protein-protein interactions in Alzheimer's
disease. This technology describes a bifunctional molecule with high
specificity for beta amyloid proteins that is applicable for in vivo
imaging. The molecule contains two moieties with different binding
affinities, one moiety has an affinity for amyloid beta proteins, and
the other moiety has an affinity for a tissue-specific chaperone. The
different moieties of the subject invention are conjoined by an inert
linkage group, typically comprised of a hydrocarbon chain, peptide, or
carbohydrate. The subject invention is affixed with a label, such as a
fluorophore or radioisotope, which adheres to the binding site of the
beta amyloid protein, the chaperone, or the linkage group. The choice
of label makes the subject invention versatile and employable in
several types of imaging modalities such as single photon emission
computed tomography (SPECT), positron emission tomography (PET),
magnetic resonance imaging (MRI), and computerized tomography (CT)
scans.
Applications: (1) Applicable for identification of beta amyloid
plaques in patients with or at risk for Alzheimer's disease and pre-
plaque amyloid beta proteins; (2) Applicable for in vivo imaging
protein-protein interactions using small molecules; (3) Applicable for
image guided therapy of Alzheimer's disease.
Market: (1) Alzheimer's disease affects approximately 4.5 million
people within the United States; (2) The direct and indirect annual
costs associated with Alzheimer's disease are at least $100 billion.
Development Status: Pre-clinical data is available.
Inventors: King C. Li and S. Narasimhan Danthi (CC).
Patent Status: U.S. Provisional Application No. 60/815,740 filed 21
Jun 2006 (HHS Reference No. E-046-2006/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Chekesha S. Clingman , Ph.D.; 301-435-5018;
clingmac@mail.nih.gov.
Collaborative Research Opportunity: The National Institutes of
Health Clinical Center, Laboratory of Diagnostic Radiology Research, is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
Small Molecules for Imaging Protein-Protein Interactions. Please
contact Betty Tong, Ph.D. at 301-594-4263 for more information.
[[Page 74548]]
Methods and Systems for Identifying and Classifying Drug Targets
Description of Technology: Available for licensing and commercial
development is a novel method for a-priori evaluation of the
therapeutic relevance of gene products for various diseases, in order
to make drug development more cost-efficient. In addition, this
technology may be used to identify novel therapeutic uses for known
drugs. For example, the current invention has the potential to uncover
the role of an established cancer drug target, in an alternative
disorder such as Alzheimer's disease, thus providing an additional use
for the available cancer drug.
The multivariable model used by the method, which is based on a
training set of targets that have already passed FDA review, is capable
of ranking drug targets in terms of prospective clinical success. This
innovative approach integrates multiple datasets that describe each
single gene product from a broad range of analyses, such as
microarrays, x-ray crystallography, and phylogenetics, to rapidly
characterize a proteins structure, function, and gene regulation
information. An algorithm subsequently scores a protein's potential as
a drug target for use in future drug design studies. The resulting set
of targets is enriched 28-fold as compared to randomly selected gene
products.
Applications: (1) Early evaluation of a candidate drug target's
potential to yield a therapeutic effect, given the target's inhibitor
is provided; (2) Efficient discovery of novel drugs and drug targets;
(3) Classification of genes according to their involvement in specific
diseases.
Development Status: The technology is ready to be used in drug
discovery and development.
Inventors: Anatoly L. Mayburd (NCI), James L. Mulshine (NCI), et
al.
Patent Status: U.S. Provisional Application No. 60/788,522 filed 31
Mar 2006 (HHS Reference No. E-268-2005/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Cristina Thalhammer-Reyero, Ph.D., M.B.A.; 301-
435-4507; thalhamc@mail.nih.gov.
Systems and Methods for Intelligent Quality Control of Instruments and
Processes
Description of Technology: Available for licensing and commercial
development is a cost-effective system and method for evaluation of
instruments and processes for real-time detection of error. The subject
invention includes the capacity to identify imprecision in a variety of
data analysis tools, which may be susceptible to malfunction. Such
processes include instrumental analysis of patient specimens, assembly
line manufacturing and general plant or factory operation. This system
provides an automated platform for the dual purpose of (1) monitoring
data to detect unusual events in real time and (2) enhancement of human
and machine recognition and analysis of improper occurrences based on
time-varying patterns of measured values.
The scheme of the current system is straightforward and in general
the method involves the following steps: (1) Collection of data
elements from an instrument or process (2) counting data elements
having values within predetermined intervals of the data range (3)
applying counts of data to a neural network that monitors data trends
and (4) production of an output based on the neural network, which
demonstrates whether the instrument or process is generating results
within an appropriate range. This system is advantageous because output
is generated in real time and thus available without delay for
immediate correction of malfunctions.
Applications: (1) Quality control for processes and instruments;
(2) Automated system for real time notification of malfunctions in an
instrument or process for immediate correction of the procedure.
Development Status: The technology is fully developed.
Inventors: James M. Deleo (CIT) and Alan T. Remaley (CC).
Patent Status: U.S. Patent No. 6,556,951 issued 29 Apr 2003 (HHS
Reference No. E-042-1997/0-US-03).
Licensing Status: Available for non-exclusive and exclusive
licensing.
Licensing Contact: Cristina Thalhammer-Reyero, Ph.D., M.B.A.; 301-
435-4507; thalhamc@mail.nih.gov.
Collaborative Research Opportunity: The National Institutes of
Health Clinical Center, Radiologic and Imaging Sciences, is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
Intelligent Quality Control of Instruments. Please contact Elaine Ayres
at 301/594-3019 for more information.
Sample Delivery System With Laminar Mixing for Microvolume Biosensing
Description of Invention: The invention is a sample delivery system
with at least two microchannels connected to a sample chamber
containing a biosensor. Biosensing for studying molecular recognition
has become an important biophysical tool for biomedical research. The
system aspirates a small sample volume into the microfluidic channels
and applies a periodic oscillatory flow pattern to the sample. This
prevents sample depletion in the stagnant layer across the sensor
surface and results in efficient mixing of the sample during the
biosensor measurement. Because the oscillatory flow pattern does not
produce a net transport of the sample with time, there is a very long
incubation time of the sensor surfaces with a very small sample volume.
The new sample delivery system uses sample volumes of only 3 to 8
microliters, compared to the 25 to 200 microliter volumes of
conventional systems, which use cuvette principles or continuous flow
microfluidics. The present invention is substantially better than
existing systems with respect to biosensor contact time and required
sample volume.
Application: Sample delivery for biosensing.
Development Status: A prototype of the technology is currently
being implemented in inventor's lab and technology is ready for
commercialization.
Inventor: Peter Schuck (ORS).
Publication: M Abrantes, MT Magone, LF Boyd, P Schuck. Adaptation
of a surface plasmon resonance biosensor with microfluidics for use
with small sample volumes and long contact times. Anal Chem. 2001 Jul
1;73(13):2828-2835.
Patent Status: U.S. Patent Application No. 10/415,909 filed 05 May
2003, claiming priority to 06 Nov 2000 (HHS Reference No. E-143-2000/0-
US-03); European Patent Application No. 01990651.0 filed 11 Jun 2001
(HHS Reference No. E-143-2000/0-EP-04).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Michael A. Shmilovich, Esq.; 301/435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NIH Office of Research
Services, Division of Bioengineering and Physical Science, Protein
Biophysics Resource, is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize this Sample Delivery System technology.
Please contact Dr. Peter Schuck at 301-435-1950 or
pschuck@helix.nih.gov for more information.
[[Page 74549]]
Vaccine for Dengue Virus
Description of Technology: The claimed invention relates to viable
chimeric dengue viruses or their derived recombinant mutants for use as
vaccines against dengue and other flavivirus diseases, including tick-
borne encephalitis and West Nile encephalitis. Dengue is a mosquito-
transmitted viral disease which occurs in tropical and subtropical
regions throughout the world. Inactivated whole dengue virus vaccines
have been shown to be insufficiently immunogenic and live dengue virus
vaccines prepared by serial passage in cell culture have not been shown
to be consistently attenuated. A dengue vaccine is still not available.
The present invention represents a technical breakthrough, which
provides new approaches to dengue vaccines by construction of chimeric
dengue viruses of all four serotypes and strategic modification to
produce attenuated virus strains. Several fields of use remain
available for licensing.
Applications: Prevention of dengue outbreaks, severe and fatal
dengue caused by dengue viruses, a major public health problem in
tropical and subtropical regions.
Inventors: Ching-juh Lai, et al. (NIAID).
Patent Status: U.S. Patent 6,184,024 issued 06 Feb 2001 (HHS
Reference No. E-171-1988/1-US-02); U.S. Patent 6,676,926 issued 13 Jan
2004 (HHS Reference No. E-171-1988/1-US-03).
Licensing Status: Available for non-exclusive licensing.
Licensing Contact: Peter A. Soukas, J.D.; 301-435-4646;
soukasp@mail.nih.gov.
Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial
Virus
Description of Technology: Available for licensing through a
Biological Materials License Agreement are the murine MAbs described in
Beeler et al, ``Neutralization epitopes of the F glycoprotein of
respiratory syncytial virus: effect of mutation upon fusion function,''
J Virol. 1989 Jul;63(7):2941-2950. The MAbs that are available for
licensing are the following: 1129, 1153, 1142, 1200, 1214, 1237, 1112,
1269, and 1243. One of these MAbs, 1129, is the basis for a humanized
murine MAb (see U.S. Patent 5,824,307 to humanized 1129 owned by
MedImmune, Inc.), recently approved for marketing in the United States.
MAbs in the panel reported by Beeler et al. have been shown to be
effective therapeutically when administered into the lungs of cotton
rats by small-particle aerosol. Among these MAbs several exhibited a
high affinity (approximately 109M-1) for the RSV F glycoprotein and are
directed at epitopes encompassing amino acid 262, 272, 275, 276 or 389.
These epitopes are separate, nonoverlapping and distinct from the
epitope recognized by the human Fab of U.S. Patent 5,762,905 owned by
The Scripps Research Institute.
Applications: Research and drug development for treatment of
respiratory syncytial virus.
Inventors: Robert M. Chanock, Brian R. Murphy, Judith A. Beeler,
and Kathleen L. van Wyke Coelingh (NIAID).
Patent Status: HHS Reference No. B-056-1994/1--Research Tool.
Licensing Status: Available for non-exclusive licensing under a
Biological Materials License Agreement.
Licensing Contact: Peter A. Soukas, J.D.; 301/435-4646;
soukasp@mail.nih.gov.
Dated: December 1, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-21028 Filed 12-11-06; 8:45 am]
BILLING CODE 4140-01-P